Dr. Marjorie G. Zauderer
- Westchester Medical Center Health Network
Physicians Advanced Hematology and Oncology
19 Bradhurst Avenue, Suite 2100N
Hawthorne, NY 10532
(914) 493-8375
Doctor Overview
Dr. Marjorie G. Zauderer is a nationally recognized medical oncologist in Hawthorne, New York. She practices at WMCHealth, where she is the section chief of hematology and oncology. She is also a professor of medicine at New York Medical College. She specializes in mesothelioma as a physician and researcher.
Before joining WMCHealth, Dr. Zauderer was co-director of the mesothelioma program at Memorial Sloan Kettering. Her clinical research focuses on developing novel therapies for mesothelioma and thoracic cancers. She has participated in clinical trials for immunotherapy and other cutting-edge mesothelioma treatments. Dr. Zauderer’s work has been supported by multiple federal grants.
Doctor Fast Facts
Main Specialty: Medical Oncology
Other Interests & Specialties: Cell therapy, chemotherapy, immunotherapy, lung cancer, mesothelioma, targeted therapy and thoracic malignancies.
Certifications, Awards & Accolades: American Board Certification in Oncology, Board of Directors Chair for Mesothelioma Applied Research Foundation, Clinical Lung Cancer Editorial Board, International Mesothelioma Interest Group
Education & Experience:
- Medical Degree from Columbia University
- Residency in Internal Medicine at New York-Presbyterian Medical Center
- Fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center
Did You Know?
There are only 3,000 mesothelioma cases per year in the U.S. Many doctors have little or no experience with this rare cancer.
It is imperative to consult with an experienced mesothelioma specialist to ensure you or your loved one receives the best treatment plan possible.
Publications
Consensus Guideline for the Management of Peritoneal Mesothelioma. Ann Surg Oncol. 2025 Jun 25.
Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma. Mod Pathol. 2025 May;38(5):100706.
Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study. JTO Clin Res Rep. 2025 Jan;6(1):100756.
